Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact information

Cancer

Colorectal cancer

Jumonji domain containing 6 (JMJD6)

Mouse and in vitro studies suggest inhibiting JMJD6 signaling could be useful for treating colon cancer. In vitro, JMJD6 acted as an a-ketoglutarate- and Fe(ii)-dependent lysyl hydroxylase, which catalyzes hydroxylation of the tumor suppressor p53 to decrease its transcriptional activity. In human colon cancer cell lines and a mouse xenograft model of colorectal cancer, siRNA against Jmjd6 increased p53 activity and apoptosis and decreased tumor growth compared with control siRNA. Next steps could include screening for inhibitors of JMJD6.

SciBX 7(17); doi:10.1038/scibx.2014.489
Published online May 1, 2014

Patent and licensing status unavailable

Wang, F. et al. PLoS Biol.; published online March 25, 2014;
doi:10.1371/journal.pbio.1001819
Contact: Yongfeng Shang, Peking University Health Science Center, Beijing, China
e-mail:

yshang@hsc.pku.edu.cn
Contact: Luyang Sun, same affiliation as above
e-mail:

luyang_sun@hsc.pku.edu.cn